Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
12 April 2019 | Story Rulanzen Martin | Photo Rulanzen Martin
The Wolves
The Wolves is a play which does not conform to mainstream female stereotypes.

It is the perfect father and daughter team - Gerben Kamper, well-known actor and former drama lecturer at the University of the Free State (UFS), and his daughter Marijda Kamper, a current Drama and Theatre Arts staff member at UFS who have taken on the task of directing and producing the play, The Wolves by Sarah DeLappe.

It was a finalist for the Pulitzer Prize for Drama in 2017. “The text is regarded very highly, most drama texts do not normally get such recognition,” said Marijda.  

The play will be performed at the Scaena on the Bloemfontein Campus from Wednesday 10 April 2019.

“This play provides an excellent acting opportunity for our students. It is also nice to get a play which accommodates so many female actors,” said Marijda. Because this play digs deep within the daily struggles of being a girl, it is a sort of homage to the current #MeToo movement. It is a play about the coming-of-age for nine girls and centres in a non-stereotypical manner on the experiences, attitudes, anxiety and the adolescent hormonal changes of girls in the contemporary world. 

“It is very exciting to be back at the department. Especially with this play. It is very different from the usual plays we get. As it is set on an indoor soccer field, it is quite a different ballgame. This play provides the opportunity to focus on all the facets of acting,” said Gerben. 

The play has six scenes and takes place just before the start of a soccer match. “So the girls are busy with warm-up exercises just minutes before the whistle,” said Marijda. “The soccer unit at KovsieSport helped us a lot. They arranged a real soccer coach to assist us, and for two weeks she trained our girls like real soccer players.”



News Archive

New research informs improved treatment of brain inflammation
2017-10-13

Description: Sebolai and Ogundeji Tags: Microbiologist, Dr Adepemi Ogundeji,  

Dr Adepemi Ogundeji, researcher in the Department of Microbial,
Biochemical and Food Biotechnology at the
University of the Free State,
and Dr Olihile Sebolai,
her study leader from the same department.
Photo: Charl Devenish



Microbiologist Dr Adepemi Ogundeji has uncovered a new use for an old medicine that can potentially save lives and money. Under the guidance of her study leader, Dr Olihile Sebolai, Dr Ogundeji set out to fight a fungal disease caused by Cryptococcus neoformans. Drs Ogundeji and Sebolai are from the University of the Free State Department of Microbial, Biochemical and Food Biotechnology. 

Dr Ogundeji is passionate about education. “My aim will always be to transfer knowledge and skills in the microbiology field,” she said. “Dr Ogundeji’s study is celebrated in that it found a new purpose for existing medicines. An advantage of repositioning old medicines is by-passing clinical trials, which sometimes take 20 years, and the safety of such medicines is already known,” Dr Sebolai, explained.

Cryptococcus infections are difficult to control and often lead to brain inflammation. In layman’s terms: “Your brain is on fire”. People with HIV/Aids are especially vulnerable, surviving only about three months without treatment. Such patients may present with a Cryptococcus-emergent psychosis, and some with an out-of-control inflammatory condition when initiated on ARVs. 

Dr Ogundeji found that the clinically recommended dosage of aspirin (anti-inflammatory medicine), and quetiapine (anti-psychotic medicine) is sufficient to control the infection. Her exceptional work was readily published in some of the foremost journals in her field, namely, Antimicrobial Agents and Chemotherapy and Frontiers in Microbiology

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept